Novartis Ag (NVS) Cash & Equivalents Growth (3y) (2012 - 2025)
Novartis Ag (NVS) Cash & Equivalents Growth (3y) (2012 - 2025) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Cash & Equiv. Growth (3y) (Qtr) |
| 1 |
Eli Lilly |
1,066.16 Bn |
1,060.88 Bn |
16.22 Bn |
14.21% |
| 2 |
Johnson & Johnson |
611.69 Bn |
589.64 Bn |
15.96 Bn |
4.20% |
| 3 |
AbbVie |
444.34 Bn |
434.99 Bn |
10.78 Bn |
11.85% |
| 4 |
Astrazeneca |
284.94 Bn |
277.05 Bn |
12.61 Bn |
6.65% |
| 5 |
Merck |
224.23 Bn |
218.58 Bn |
12.09 Bn |
-18.13% |
| 6 |
Amgen |
195.12 Bn |
183.08 Bn |
5.87 Bn |
-27.48% |
| 7 |
Gilead Sciences |
156.45 Bn |
148.73 Bn |
5.52 Bn |
15.61% |
| 8 |
Pfizer |
136.01 Bn |
123.24 Bn |
-1.21 Bn |
-7.70% |
| 9 |
Novartis Ag |
113.45 Bn |
113.67 Bn |
- |
- |
| 10 |
Biogen |
30.87 Bn |
26.59 Bn |
1.82 Bn |
5.29% |
| Date | Value |
|---|
| Dec 31, 2025 |
-29.99% |
| Jun 30, 2025 |
325.04% |
| Dec 31, 2024 |
-73.08% |
| Sep 30, 2024 |
194.72% |
| Jun 30, 2024 |
996.18% |
| Mar 31, 2024 |
117.81% |
| Dec 31, 2023 |
11.51% |
| Sep 30, 2023 |
104.29% |
| Jun 30, 2023 |
425.63% |
| Dec 31, 2022 |
-12.22% |
| Jun 30, 2022 |
-26.18% |
| Mar 31, 2022 |
-48.04% |
| Dec 31, 2021 |
-2.22% |
| Jun 30, 2021 |
-92.16% |
| Dec 31, 2020 |
2.92% |
| Dec 31, 2019 |
16.61% |
| Dec 31, 2018 |
41.60% |
| Jun 30, 2018 |
-76.83% |
| Dec 31, 2017 |
879,410.23% |
| Dec 31, 2016 |
88,719.99% |
